. Pfizer's stock performance has been far from thrilling this year, with shares down 3.87% year-to-date. In contrast, the S&P 500 has surged over 21%, making Pfizer look like the laggard of the pack.

The decrease in PFE stock over the last few years has been far from consistent, with annual returns being considerably more volatile than the S&P 500. Returns for PFE stock were 67% in 2021, -10% ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry.

In the three months ended September 29, Pfizer's revenue increased 31.3% year over year to $17.7 billion. What's more, the company swung to a net profit of $1.06 per share from a loss of 17 cents ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

PFE stock has faced a notable decline of 30% from levels of $35 in early January 2021 to around $25 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period.